Levetiracetam Rudipharm

Levetiracetam, the active ingredient in Levetiracetam Rudipharm, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the management of partial seizures, generalized tonic‑clonic seizures and other epilepsy syndromes in patients who require effective seizure control.

GNH USA supplies Levetiracetam Rudipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is used to treat several seizure types within the epilepsy disease family. - Partial seizures: reduces the frequency of focal onset seizures in adults and children. - Generalized tonic-clonic seizures: helps prevent convulsive seizures in patients with generalized epilepsy. - Epilepsy (adjunct therapy): provides additional seizure control when combined with other antiepileptic drugs.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or low in energy. - Headache: mild to moderate head pain. - Nausea: upset stomach or urge to vomit. - Irritability: mood changes or increased agitation. - Somnolence: excessive sleepiness during the day.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood or behavior changes: depression, anxiety, or suicidal thoughts. - Hematologic abnormalities: low blood cell counts. - Stevens‑Johnson syndrome: severe skin blistering. - Hepatic dysfunction: elevated liver enzymes or liver injury.

Before prescribing Levetiracetam, clinicians should consider several safety precautions. - Renal impairment: adjust dose in patients with reduced kidney function. - History of psychiatric disorders: monitor for mood changes or suicidal ideation. - Concomitant CNS depressants: use caution as combined effects may increase sedation. - Pregnancy: evaluate risk‑benefit ratio; limited data available. - Driving and operating machinery: advise patients about possible dizziness or somnolence. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can decrease levetiracetam concentrations. - Phenytoin: may lower levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, monitor for toxicity. - Other antiepileptic drugs: combined CNS depression may enhance sedation. - Oral contraceptives: levetiracetam may reduce hormonal contraceptive efficacy.